David Lebowitz
Stock Analyst at Citigroup
(4.32)
# 854
Out of 5,182 analysts
119
Total ratings
59.77%
Success rate
14.75%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $73.27 | +14.64% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $65.32 | +28.60% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $33.29 | +44.19% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $11.79 | +69.64% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $229.27 | +26.49% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $94.65 | +8.82% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.75 | +16.03% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $36.81 | -40.23% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $73.28 | -8.57% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $44.94 | +24.61% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.63 | -26.63% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.24 | +20.97% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $68.23 | -34.05% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $91.49 | -25.67% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $512.39 | -25.45% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.18 | +80.52% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.04 | +98.68% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $305.54 | -46.32% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $23.26 | +67.67% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.39 | -1.82% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $8.66 | +4,576.67% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.93 | +256.23% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $73.27
Upside: +14.64%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $65.32
Upside: +28.60%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $33.29
Upside: +44.19%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $11.79
Upside: +69.64%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $229.27
Upside: +26.49%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $94.65
Upside: +8.82%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.75
Upside: +16.03%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $36.81
Upside: -40.23%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $73.28
Upside: -8.57%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $44.94
Upside: +24.61%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.63
Upside: -26.63%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.24
Upside: +20.97%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $68.23
Upside: -34.05%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $91.49
Upside: -25.67%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $512.39
Upside: -25.45%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.18
Upside: +80.52%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.04
Upside: +98.68%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $305.54
Upside: -46.32%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $23.26
Upside: +67.67%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.39
Upside: -1.82%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $8.66
Upside: +4,576.67%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.93
Upside: +256.23%